Sorafenib Teva 200 mg 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sorafenib teva 200 mg

teva pharmaceuticals slovakia s.r.o., slovensko - sorafenib - 44 - cytostatica

Weldinin 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

weldinin

egis pharmaceuticals plc, maďarsko - sorafenib - 44 - cytostatica

Sorafenib Accord 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastické činidlá - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.